Program Overview and Target Audience
The joint providers of Medical Education Resources (MER), the Chronic Liver Disease Foundation (CLDF), and the Global NASH Council (GNC) present Major Advancement in MASH Management. This accredited hybrid symposium has been designed to meet the educational needs of gastroenterologists, hepatologists, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals who are currently managing and treating patients with metabolic dysfunction-associated steatohepatitis (MASH).
Educational Objectives
Upon completion of this activity, participants should be able to:
-
Assess the epidemiologic impact of MASLD
-
Discuss the Use of NITs in MASLD
-
Explain initial treatment with Lifestyle Modification and approved medication for cardio-metabolic risks (obesity and type 2 diabetes)
-
Review data on the currently approved medication for MASH
-
Review data about drugs in Phase 3 clinical trials of MASH
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the Chronic Liver Disease Foundation (CLDF), and the Global NASH Council (GNC). MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
ACCME Statement
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
MER, the Chronic Liver Disease Foundation, and the Global NASH Council planners have no relevant financial relationships to disclose.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, the Chronic Liver Disease Foundation, and the Global NASH Council and/or Madrigal Pharmaceuticals. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Fee information
There is no fee for this educational activity.